title: Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction.
abstract: Fifty-nine consecutive patients presenting within 6 hours of the onset of symptoms of an acute myocardial infarction were treated with 150 mg of soluble aspirin orally, and either 70 or 100 mg of alteplase divided into 2 intravenous bolus injections separated by 30 minutes. Dosage regimens were either 20 followed by 50 mg (group A), 50 followed by 20 mg (group B), or 50 followed by 50 mg (group C). Coronary angiography 60 minutes after the first bolus showed infarct-related coronary artery patency (Thrombolysis in Myocardial Infarction score 2 or 3) in 13 of 16 (81%) patients in group A, 12 of 17 (71%) in group B, and 10 of 11 (91%) in group C (overall patency rate at 60 minutes: 35 of 44 [80%] patients; 95% confidence interval 68 to 91%). At 90 minutes, patency rates were 15 of 20 (75%) patients in both groups A and B, and 18 of 19 (95%) in group C (overall patency rate 48 of 59 [81%] patients; 95% confidence interval 72 to 91%). Residual thrombus was identified with the 90-minute angiogram in 7 patients in group A, 5 in group B, and 3 in group C. Although there was no statistically significant difference in patency between the 3 dosage regimens at either 60 or 90 minutes there was a trend toward increased patency and more complete thrombolysis at 90 minutes in group C. No episodes of bradyarrhythmia, hypotension or cerebrovascular bleeding were observed after double bolus therapy. There were 7 episodes (12%) of reocclusion, and 3 deaths (5%) within 1-month follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland.
authors.forename: J A
authors.initials: JA
authors.lastname: Purvis
authors.forename: T G
authors.initials: TG
authors.lastname: Trouton
authors.forename: M J
authors.initials: MJ
authors.lastname: Roberts
authors.forename: P
authors.initials: P
authors.lastname: McKeown
authors.forename: M G
authors.initials: MG
authors.lastname: Mulholland
authors.forename: G W
authors.initials: GW
authors.lastname: Dalzell
authors.forename: C M
authors.initials: CM
authors.lastname: Wilson
authors.forename: G C
authors.initials: GC
authors.lastname: Patterson
authors.forename: S W
authors.initials: SW
authors.lastname: Webb
authors.forename: M M
authors.initials: MM
authors.lastname: Khan
mesh_terms: D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000032:analysis; D003251:Constriction, Pathologic / Q000473:pathology; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000473:pathology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D010959:Tissue Plasminogen Activator